1. A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study.
- Author
-
Takada, Kazuki, Shimokawa, Mototsugu, Takamori, Shinkichi, Shimamatsu, Shinichiro, Hirai, Fumihiko, Tagawa, Tetsuzo, Okamoto, Tatsuro, Hamatake, Motoharu, Tsuchiya-Kawano, Yuko, Otsubo, Kohei, Inoue, Koji, Yoneshima, Yasuto, Tanaka, Kentaro, Okamoto, Isamu, Nakanishi, Yoichi, and Mori, Masaki
- Subjects
NON-small-cell lung carcinoma ,STATINS (Cardiovascular agents) ,CANCER prognosis ,PROGRESSION-free survival ,TREATMENT effectiveness ,DYSLIPIDEMIA - Abstract
Background: Many studies have recently reported the association of concomitant medications with the response and survival in patients with non-small-cell lung cancer (NSCLC) treated with cancer immunotherapy. However, the clinical impact of statin therapy on the outcome of cancer immunotherapy in patients with NSCLC is poorly understood. Methods: In our database, we retrospectively identified and enrolled 390 patients with advanced or recurrent NSCLC who were treated with anti-programmed cell death-1 (PD-1) monotherapy in clinical practice between January 2016 and December 2019 at 3 medical centers in Japan to examine the clinical impact of statin therapy on the survival of patients with NSCLC receiving anti-PD-1 monotherapy. A propensity score-matched analysis was conducted to minimize the bias arising from the patients' backgrounds. Results: The Kaplan–Meier curves of the propensity score-matched cohort showed that the overall survival (OS), but not the progression-free survival (PFS), was significantly longer in patients receiving statin therapy. However, a Cox regression analysis in the propensity score-matched cohort revealed that statin therapy was not an independent favorable prognostic factor, although it tended to be correlated with a favorable outcome. Conclusions: Statin therapy may be a combination tool for cancer immunotherapy in patients with NSCLC. These findings should be validated in further prospective studies with larger sample sizes. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF